TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy

Bortezomib (bort) is an effective therapeutic agent for patients with multiple myeloma (MM); however, most patients develop drug resistance. Autophagy, a highly conserved process that recycles cytosol or entire organelles via lysosomal activity, is essential for the survival, homeostasis, and drug r...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jing, Cao, Wen, Huang, Xi, Chen, Qingxiao, Ye, Shuting, Qu, Jianwei, Liu, Yang, Guo, Xing, Yao, Shunnan, Zhang, Enfan, He, Jingsong, Li, Anqi, Yang, Li, Cai, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561007/
https://www.ncbi.nlm.nih.gov/pubmed/37083684
http://dx.doi.org/10.1182/bloodadvances.2022008241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561007/
https://www.ncbi.nlm.nih.gov/pubmed/37083684
http://dx.doi.org/10.1182/bloodadvances.2022008241

Ejemplares similares